Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers

• Published in: Clinical and translational science Vol. 17; no. 8; pp. e13891 - n/a
• Main Authors: Badorrek, Philipp, Diefenbach, Claudia, Kögler, Harald, Eleftheraki, Anastasia, Seitz, Friedeborg, Hohlfeld, Jens M.
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.08.2024; Wiley
• Subjects: Adolescent; Adult; Antifungal agents; Bacterial infections; Bioavailability; Blood; Bone marrow; Bronchiectasis; Bronchiectasis - drug therapy; Cathepsin C - antagonists & inhibitors; Cathepsin C - metabolism; Clinical trials; Dipeptidyl-peptidase I; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Drug interaction; Drug Interactions; Elastase; Female; Food; Food-Drug Interactions; Healthy Volunteers; Hispanic Americans; Humans; Infections; Inflammation; Itraconazole; Itraconazole - administration & dosage; Itraconazole - adverse effects; Itraconazole - pharmacokinetics; Itraconazole - pharmacology; Leukocytes (neutrophilic); Male; Medical treatment; Middle Aged; Mortality; Neutrophils; Oral administration; Pharmacodynamics; Pharmacokinetics; Proteinase 3; Serine proteinase; Young Adult
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.13891

Novel treatments are needed to reduce inflammation, improve symptoms, address exacerbations, and slow disease progression in bronchiectasis. Cathepsin C (CatC) inhibition promises to achieve this through reduction of neutrophil‐derived serine protease (including neutrophil elastase [NE] and proteinase 3 [PR3]) activation. Here, we present the phase I characterization of the novel CatC inhibitor, BI 1291583. Five phase I trials of BI 1291583 in healthy subjects are presented: a single‐rising‐dose study (NCT03414008) and two multiple‐rising‐dose studies (NCT03868540 and NCT04866160) assessing the safety, tolerability, pharmacodynamics, and pharmacokinetics of BI 1291583; a food effect study (NCT03837964); and a drug–drug interaction study (NCT03890887) of BI 1291583 and itraconazole. BI 1291583 was safe and well tolerated across the doses tested in these trials. Most adverse events (AEs) were mild or moderate in intensity, with no serious AEs, AEs of special interest or deaths reported in any trial. Drug‐related skin exfoliation was not reported more frequently in subjects treated with BI 1291583 compared with placebo. BI 1291583 was readily absorbed, and pharmacokinetics were supra‐proportional over the dose ranges assessed. Additionally, BI 1291583 inhibited CatC in a dose‐dependent manner, inhibited downstream NE activity, and decreased PR3 levels. No food effect was observed. Co‐administration of multiple doses of itraconazole increased BI 1291583 exposure approximately twofold. Due to these promising phase I results, a multinational phase II program of BI 1291583 in adults with bronchiectasis is ongoing (Airleaf™ [NCT05238675], Clairafly™ [NCT05865886], and Clairleaf™ [NCT05846230]).